[Click eStock] "NewGeneLabPharma, Good Short- and Long-Term Portfolio of New Drug Candidates"

[Asia Economy Reporter Jang Hyowon] SangSangIn Securities analyzed on the 22nd that NewGeneLab Pharma is a leading domestic bio company in metabolic anticancer drugs, and with the increasing possibility of domestic commercialization of the targeted anticancer drug Taletrectinib, a green light has been turned on for mid- to short-term cash cow creation. No investment opinion or target price was presented.

Researcher Ha Taegi of SangSangIn Securities explained, “NewGeneLab Pharma holds the domestic distribution rights through a license for Taletrectinib, developed by Japan's Daiichi Sankyo,” and added, “Taletrectinib has completed Phase 1 clinical trials in the US and Japan and is currently undergoing global Phase 2 clinical trials, while domestic clinical trials are being conducted by NewGeneLab Pharma.”

He analyzed, “If the global Phase 2 clinical trial of Taletrectinib is completed in the first half of 2023 and an NDA (New Drug Application) is submitted based on the Phase 2 data, conditional sales could be possible in 2024,” and added, “It is also possible to expect a domestic distribution rights contract with a major domestic pharmaceutical company around the completion of the Phase 2 clinical trial in 2023.”

Researcher Ha Taegi explained, “The metabolic anticancer drug KAT is a new drug substance made from 3BP that induces cancer cells to self-destruct by interfering with their metabolic activity,” and said, “In April, it obtained IND (Investigational New Drug) approval for Phase 1/2a clinical trials from the US FDA for liver cancer patients, and patient dosing for the first cohort of Phase 1 clinical trials will begin in late December.”

He said, “The Phase 1 clinical trial of KAT is expected to take about 1 year and 6 months, aiming to finish by 2023, and Phase 2 clinical trials will be conducted independently,” and added, “The interim results of Phase 1 will be officially presented at the 2023 AACR (American Association for Cancer Research) or ASCO (American Society of Clinical Oncology).”

Researcher Ha Taegi emphasized, “NewGeneLab Pharma’s new drug pipeline portfolio is well positioned for both short and long term, making it quite stable,” and said, “In the short term, we can expect the announcement of Phase 2 clinical trial results of Taletrectinib in 2023 and commercialization possibilities in 2024, and in the long term, there is a growth vision for the metabolic anticancer drug KAT.”